Applications of Microarrays and Biochips in Pharmacogenomics

  • Gary Hardiman
Part of the Methods in Molecular Biology™ book series (MIMB, volume 448)


The complete sequence of the human genome and subsequent intensive searches for polymorphic variations are providing the prerequisite markers necessary to facilitate elucidation of the genetic variability in drug responses. Improvements in the sensitivity and precision of DNA microarrays permit a detailed and accurate scrutiny of the human genome. These advances have the potential to significantly improve health care management by improving disease diagnosis and targeting molecular therapy. Pharmacogenetic approaches, in limited use today, will become an integral part of therapeutic monitoring and health management, permitting patient stratification in advance of treatments, with the potential to eliminate adverse drug reactions. In this chapter, the current state of biochip technology is discussed, and recent applications in the arena of clinic diagnostics are explored.


AmpliChip biochips microarrays P450 pharmacogenetics 


  1. 1.
    Marton, M. J., DeRisi, J. L., Bennett, H. A., et al. (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293–1301.CrossRefPubMedGoogle Scholar
  2. 2.
    Vilo, J., and Kivinen, K. (2001) Regulatory sequence analysis: application to the interpretation of gene expression. Eur. Neuropsychopharmacol. 11, 399–411.CrossRefPubMedGoogle Scholar
  3. 3.
    Hardiman, G. Microarrays technologies 2006: an overview (2006). Pharmacogenomics. 8, 1153–1158.CrossRefGoogle Scholar
  4. 4.
    Waring, J.F., Ciurlionis, R., Jolly, R.A., Heindel, M., and Ulrich, R.G. (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359–368.CrossRefPubMedGoogle Scholar
  5. 5.
    Hamadeh, H.K., Amin, R.P., Paules, R.S., and Afshari, C.A. (2002) An overview of toxicogenomics. Curr. Issues Mol. Biol. 4, 45–56.PubMedGoogle Scholar
  6. 6.
    Johnson, J.A. (2001) Drug target pharmacogenomics: an overview. Am. J. Pharmacogenomics. 1, 271–281.CrossRefPubMedGoogle Scholar
  7. 7.
    Kruglyak, L., and Nickerson, D.A. (2001) Variation is the spice of life. Nat. Genet. 27, 234–236.CrossRefPubMedGoogle Scholar
  8. 8.
    Ensom, M.H., Chang, T.K., and Patel, P. (2001) Pharmacogenetics: the therapeutic drug monitoring of the future? Clin. Pharmacokinet. 40, 783–802.CrossRefPubMedGoogle Scholar
  9. 9.
    Routledge, P.A., O'Mahony, M.S., and Woodhouse, K.W. (2004). Adverse drug reactions in elderly patients. Br. J. Clin. Pharmacol. 57, 121–126.CrossRefPubMedGoogle Scholar
  10. 10.
    Lundkvist, J., and Jönsson, B. (2004) Pharmacoeconomics of adverse drug reactions. Fund. Clin. Pharmacol. 18, 275–280.Google Scholar
  11. 11.
    Obayashi, K., Nakamura, K., Kawana, J., et al. (2006) VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169–178.CrossRefPubMedGoogle Scholar
  12. 12.
    Eichelbaum, M., Ingelman-Sundberg, M., and Evans, W.E. (2006) Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119–137.CrossRefPubMedGoogle Scholar
  13. 13.
    Desta, Z., Zhao, X., Shin, J.G., and Flockhart, D.A. (2002) Clinical significance of the cyto-chrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913–958.CrossRefPubMedGoogle Scholar
  14. 14.
    de Leon, J., Armstrong, S.C., and Cozza Kelly, L. (2006) Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 47, 75–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Bodor, M., Kelly, E.J., and Ho, R.J. (2005) Characterization of the human MDR1 gene. AAPS J. 07, E1–E5.CrossRefGoogle Scholar
  16. 16.
    Southern, E.M. (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98, 503–517.CrossRefPubMedGoogle Scholar
  17. 17.
    Wallace, R.B., Shaffer, J., Murphy, R.F., Bonner, J., Hirose, T., and Itakura, K. (1979) Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. Nucleic Acids Res. 6, 3543–3557.CrossRefPubMedGoogle Scholar
  18. 18.
    Chee, M., Yang, R., Hubbell, E., et al. (1996) Accessing genetic information with high-density DNA arrays. Science. 274, 610–614.CrossRefPubMedGoogle Scholar
  19. 19.
    Schena, M., Shalon, D., Davis, R.W., and Brown, P.O. (1995) Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270, 467–470.CrossRefPubMedGoogle Scholar
  20. 20.
    Bowtell, D.D.L. (1999) Options available–from start to finish for obtaining expression data by microarray. Nat. Genet. 21, 25–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Hardiman, G. (2004) Microarray platforms–comparisons and contrasts. Pharmacogenomics, 5, 487–502.CrossRefPubMedGoogle Scholar
  22. 22.
    Wick, I., and Hardiman, G. (2005) Biochip platforms as functional genomics tools for drug discovery. Curr. Opin. Drug Discov. Dev. 8, 347–354.Google Scholar
  23. 23.
    Gunderson, K.L., Steemers, F.J., Lee, G., Mendoza, L.G., and Chee, M.S. (2005) A genome-wide scalable SNP genotyping assay using microarray technology. Nat. Genet. 37, 549–554.CrossRefPubMedGoogle Scholar
  24. 24.
    Steemers, F.J., Chang, W., Lee, G., Barker, D.L., Shen, R., and Gunderson, K.L. (2006) Whole-genome genotyping with the single-base extension assay. Nat. Methods. 3, 31–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Mahant, V., Kureshy, F., Vairavan, R., and Hardiman, G. (2003) The INFINITI system–an automated multiplexing microarray platform, in Microarray Methods and Applications, vol. 16 (G. Hardiman, ed.), DNA Press, Eagleville, PA, pp. 325–328.Google Scholar
  26. 26.
    Kim, P., Fu, Y.K.K., Mahant, V., Kureshy, F., Hardiman, G., and Corbeil, J. (2006) The next generation of automated microarray platform for a multiplexed CYP2D6 assay, in Biochips as Pathways to Discovery, vol. 6 (A. Carmen and G. Hardiman, eds.) Taylor and Francis, New York, pp. 97–108.CrossRefGoogle Scholar
  27. 27.
    Gygi, S.P., Rochon, Y., Franza, B., and Abersold, R. (1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720–1730.PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Gary Hardiman
    • 1
  1. 1.BIOGEM, and Department of MedicineUniversity of California San DiegoLa JollaUSA

Personalised recommendations